- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05028166
Individual Patient Compassionate Use of Mirdametinib
March 13, 2024 updated by: SpringWorks Therapeutics, Inc.
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Study Overview
Status
Available
Conditions
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: SpringWorks Medical Information
- Phone Number: (888) 400-7989
- Email: medinfo@springworkstx.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 months and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
- Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.
- Patient does not qualify to participate in an ongoing clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
August 24, 2021
First Submitted That Met QC Criteria
August 24, 2021
First Posted (Actual)
August 31, 2021
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 13, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neoplasms, Nerve Tissue
- Peripheral Nervous System Diseases
- Nervous System Neoplasms
- Heredodegenerative Disorders, Nervous System
- Neoplastic Syndromes, Hereditary
- Nerve Sheath Neoplasms
- Neurocutaneous Syndromes
- Peripheral Nervous System Neoplasms
- Neurofibromatoses
- Neurofibromatosis 1
- Neurofibroma
- Neurofibroma, Plexiform
Other Study ID Numbers
- MEK-NF1-701
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
-
Novartis PharmaceuticalsTerminatedPlexiform Neurofibroma Associated With Neurofibromatosis Type 1Israel
-
AstraZenecaCompletedHealthy Participants | Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)United States
-
National Cancer Institute (NCI)CompletedPlexiform Neurofibroma | Neurofibromatosis Type IUnited States
-
SpringWorks Therapeutics, Inc.Active, not recruitingPlexiform Neurofibroma | Neurofibromatosis Type 1 (NF1)United States
-
National Cancer Institute (NCI)Active, not recruitingNeurofibromatosis 1 (NF1) | Plexiform Neurofibromas (PN)United States
-
AstraZenecaApproved for marketingNF type1 With Inoperable Plexiform NeurofibromasUnited States
-
AstraZenecaMerck Sharp & Dohme LLCCompletedNeurofibromatosis 1 | Neurofibroma PlexiformChina
-
University of Alabama at BirminghamPacific Pediatric Neuro-Oncology Consortium; Array BioPharmaActive, not recruitingNeurofibromatosis Type 1 | Plexiform NeurofibromaUnited States
-
Assistance Publique - Hôpitaux de ParisNovartisCompletedNeurofibromatoses | Neurofibromatosis Type 1 | Plexiform NeurofibromaFrance
-
National Cancer Institute (NCI)TerminatedNeurofibromatosis Type 1 | Plexiform Neurofibroma | Spinal Cord NeurofibromaUnited States
Clinical Trials on Mirdametinib (MEK Inhibitor)
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
CStone PharmaceuticalsCompletedSolid Tumor, AdultAustralia
-
Henan Cancer HospitalRecruitingDigestive System TumorsChina
-
Array Biopharma, now a wholly owned subsidiary...Completed
-
Array Biopharma, now a wholly owned subsidiary...Completed
-
University Hospital, CaenActive, not recruiting
-
Array Biopharma, now a wholly owned subsidiary...CompletedRheumatoid ArthritisBrazil, Argentina, United States, Poland, Hungary, Peru, Romania
-
National Cancer Institute (NCI)Completed
-
Children's Hospital Medical Center, CincinnatiRecruitingHistiocytic Disorders | Juvenile Xanthogranuloma (JXG) | Langerhans Cell Histiocytosis (LCH) | Rosai-Dorfman Disease (RDD)United States
-
Atriva Therapeutics GmbHSGS Life Sciences, a division of SGS Belgium NVCompleted